Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

By sjmartinez • September 22, 2022

Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2022 Sep 22:annrheumdis-2022-222259. doi: 10.1136/ard-2022-222259. Epub ahead of print. PMID: 36137735.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics

Ambient AI Scribes in Clinical Practice: A Randomized Trial

Lukac PJ, Turner W, Vangala S, Chin AT, Khalili J, Shih YT, Sarkisian C, Cheng EM, Mafi JN. Ambient AI Scribes in Clinical Practice: A[...]

North American and European practices for opioid-sparing and opioid-free anaesthesia: a cross-sectional survey

Gricourt Y, Boulos NM, Daoulas Y, Grogan T, Alexander B, Mezzarobba M, Cuvillon P, Pogatzki-Zahn EM, Beloeil H, Cannesson M, Forget P, Joosten A. North[...]

Amara Yad Image: The 3-Chamber View-Inferomedial Segment

Shivkumar K, Mori S. Amara Yad Image: The 3-Chamber View-Inferomedial Segment. J Am Coll Cardiol. 2026 Jan 6;87(1):117-119. doi: 10.1016/j.jacc.2025.10.037. PMID: 41498475.